Clinical features of tumor necrosis factor-α-inhibitor induced chilblain lupus: A case series

Shabeeb, Nadine; Hinshaw, Molly; Pei, Susan; Craddock, Lauren; Keenan, Thomas; Endo, Justin

doi:10.1016/j.jdcr.2021.04.006

Cited by 6 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 8 Drug-induced chilblain lupus is rare and predominantly reported in patients on tumor necrosis factor inhibitors. 2 Although there have not been reports of belatacept-induced lupus, there have been 3 prior reports on abatacept, belatacept's parent compound, causing drug-induced subacute cutaneous lupus erythematosus (SCLE) and 1 report on systemic lupus erythematosus with membranous nephropathy associated with abatacept. 9 , 10 , 11 , 12 In all of these cases, as with our patient, a longstanding history of autoimmune disease preceded the initiation of the costimulatory blockade.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case of belatacept-induced chilblain lupus

et al. 2022

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Drug-induced chilblain lupus is rare and has previously been reported predominantly in patients on tumor necrosis factor inhibitors and abatacept. 2 We herein report a case of a man with a recent renal transplant who was started on belatacept and subsequently developed CHLE. The rash resolved with the discontinuation of the medication.…”

Section: Introductionmentioning

confidence: 96%

A case of belatacept-induced chilblain lupus

et al. 2022

View full text Add to dashboard Cite

“…Fluorouracil compounds 2 , capecitabine, tegafur, and uracil/tegafur 64 Non-steroidal anti-inflammatory drugs 7 , Anti-TNFα (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab 7 ), Antifungals, intravenous immunoglobulin 65 Other forms of cutaneous LE Lupus tumidus: ustekinumab, bortezomide 58 "Chilblain lupus": infliximab, adalimumab, etarnecept 58 Rowell syndrome: terbinafine 7 LE: lupus erythematosus.…”

Section: Chronic Cutaneous Lementioning

confidence: 99%

Drug-induced lupus erythematosus

Gouveia,

Gonçalo

2023

PJDV

View full text Add to dashboard Cite

Drug-induced lupus erythematosus is an autoimmune disease with unexpected onset after treatment with certain drugs. Clinically, this disease is very similar to idiopathic lupus erythematosus, although its manifestations are typically milder. In addition, the laboratory and histological changes of the induced forms are also not significantly different from the idiopathic condition, sometimes making the diagnosis of the drug-induced form a challenge for clinicians. This entity has been gaining relevance in the clinical setting and the number of drugs associated with it has been increasing, mainly due to the emergence of new biological therapies with a strong causal link with drug-induced lupus, such as tumor necrosis factor-alpha inhibitors. However, there are still no universally accepted diagnostic criteria to identify this disease, and information about its pathophysiology is still somewhat scarce, making it difficult to predict the most likely culprit drugs before there are enough reports to establish a strong link. In addition, although some risk factors have shown susceptibility for certain individuals, they are not yet fully understood. Given the possibility of disease reversal by the withdrawal of the offending drug, it is extremely important to be aware of the possible implication of a drug in the pathogenesis of this disease, and for clinicians who approach patients with lupus manifestations, particularly cutaneous manifestations, it is mandatory to look for the onset of new drugs used by the patient. This review will systematize the current knowledge about this drug-induced lupus, in terms of pathophysiology, clinical, histopathological, and laboratory manifestations, diagnosis, and treatment, as well as the most commonly implicated drugs.

show abstract

“…ANA positivity is an excepted finding in anti-TNFα induced chilblain lupus cases. 2 Saheeb et al 4 reported three cases, in two of them anti-TNFα therapy was continued while in one case they discontinued the treatment. All of the patients were given hydroxychloroquine 400 mg daily and cutaneous symptoms resolved.…”

Section: Case Of Chilblain Lupus Triggered By Adalimumab Therapy In A...mentioning

confidence: 99%

“…All of the patients were given hydroxychloroquine 400 mg daily and cutaneous symptoms resolved. 4 Although the exact mechanism of anti-TNFα induced lupus is unclear, some possible explanations have been suggested.…”

Section: Case Of Chilblain Lupus Triggered By Adalimumab Therapy In A...mentioning

confidence: 99%